Literature DB >> 22064528

Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs.

Nick C T Schopman1, Anja Braun, Ben Berkhout.   

Abstract

Despite the success of antiretroviral drugs in decreasing AIDS-related mortality, a substantial fraction of HIV-infected patients experience therapy failure due to the emergence of drug-resistant virus variants. For durable inhibition of HIV-1 replication, the emergence of such escape viruses must be controlled. In addition to antiretroviral drugs, RNA interference (RNAi)-based gene therapy can be used to inhibit HIV-1 replication by targeting the viral RNA genome. RNAi is an evolutionary conserved gene silencing mechanism that mediates the sequence-specific breakdown of the targeted mRNA. Here we investigated an alternative strategy combining the activity of a protease inhibitor (PI) with second-generation short hairpin RNAs (shRNAs) designed to specifically block the emergence of PI-resistant HIV-1 variants. We demonstrate that dominant viral escape routes can be effectively blocked by second-generation shRNAs and that virus evolution can be redirected toward less-fit variants. These results are of importance for a deeper understanding of HIV-1 evolution under combined drug and RNAi pressure and may be used to design future therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22064528      PMCID: PMC3256055          DOI: 10.1128/AAC.05491-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells.

Authors:  S M Hammond; E Bernstein; D Beach; G J Hannon
Journal:  Nature       Date:  2000-03-16       Impact factor: 49.962

2.  Rational siRNA design for RNA interference.

Authors:  Angela Reynolds; Devin Leake; Queta Boese; Stephen Scaringe; William S Marshall; Anastasia Khvorova
Journal:  Nat Biotechnol       Date:  2004-02-01       Impact factor: 54.908

3.  Tolerance for mutations and chemical modifications in a siRNA.

Authors:  Mohammed Amarzguioui; Torgeir Holen; Eshrat Babaie; Hans Prydz
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

4.  Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.

Authors:  Virginie Perrin; Fabrizio Mammano
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 5.  25 years after HIV discovery: prospects for cure and vaccine.

Authors:  Luc Montagnier
Journal:  Virology       Date:  2010-02-20       Impact factor: 3.616

6.  Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI.

Authors:  K Peden; M Emerman; L Montagnier
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

7.  Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  W Keulen; N K Back; A van Wijk; C A Boucher; B Berkhout
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Wataru Sugiura; Zene Matsuda; Yoshiyuki Yokomaku; Kurt Hertogs; Brendan Larder; Tsuyoshi Oishi; Aiko Okano; Teiichirou Shiino; Masashi Tatsumi; Masakazu Matsuda; Hanae Abumi; Noboru Takata; Satoshi Shirahata; Kaneo Yamada; Hiroshi Yoshikura; Yoshiyuki Nagai
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  HIV evolution: CTL escape mutation and reversion after transmission.

Authors:  A J Leslie; K J Pfafferott; P Chetty; R Draenert; M M Addo; M Feeney; Y Tang; E C Holmes; T Allen; J G Prado; M Altfeld; C Brander; C Dixon; D Ramduth; P Jeena; S A Thomas; A St John; T A Roach; B Kupfer; G Luzzi; A Edwards; G Taylor; H Lyall; G Tudor-Williams; V Novelli; J Martinez-Picado; P Kiepiela; B D Walker; P J R Goulder
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

10.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

View more
  4 in total

1.  Combinatorial CRISPR-Cas9 and RNA Interference Attack on HIV-1 DNA and RNA Can Lead to Cross-Resistance.

Authors:  Na Zhao; Gang Wang; Atze T Das; Ben Berkhout
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

2.  RNA interference approaches for treatment of HIV-1 infection.

Authors:  Maggie L Bobbin; John C Burnett; John J Rossi
Journal:  Genome Med       Date:  2015-05-28       Impact factor: 11.117

Review 3.  Bone Marrow Gene Therapy for HIV/AIDS.

Authors:  Elena Herrera-Carrillo; Ben Berkhout
Journal:  Viruses       Date:  2015-07-17       Impact factor: 5.048

4.  Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing.

Authors:  Chantelle Ahlenstiel; Catalina Mendez; Steven T H Lim; Katherine Marks; Stuart Turville; David A Cooper; Anthony D Kelleher; Kazuo Suzuki
Journal:  Mol Ther Nucleic Acids       Date:  2015-10-27       Impact factor: 10.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.